Ritholtz Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.1M | Buy |
1,770
+362
| +26% | +$246K | 0.02% | 593 |
|
|
2026
Q1 | $1.09M | Buy |
1,408
+172
| +14% | +$132K | 0.02% | 529 |
|
|
2025
Q4 | $954K | Buy |
+1,236
| New | +$839K | 0.02% | 543 |
|
|
2025
Q3 | – | Sell |
-386
| Closed | -$203K | – | 1104 |
|
|
2025
Q2 | $203K | Sell |
386
-100
| -21% | -$55.8K | ﹤0.01% | 913 |
|
|
2025
Q1 | $308K | Buy |
486
+35
| +8% | +$24.1K | 0.01% | 739 |
|
|
2024
Q4 | $321K | Sell |
451
-278
| -38% | -$233K | 0.01% | 686 |
|
|
2024
Q3 | $766K | Buy |
729
+109
| +18% | +$121K | 0.02% | 439 |
|
|
2024
Q2 | $652K | Buy |
620
+54
| +10% | +$52.3K | 0.02% | 448 |
|
|
2024
Q1 | $545K | Buy |
566
+69
| +14% | +$65.6K | 0.02% | 503 |
|
|
2023
Q4 | $437K | Sell |
497
-13
| -3% | -$10.7K | 0.02% | 523 |
|
|
2023
Q3 | $420K | Buy |
510
+79
| +18% | +$62.1K | 0.02% | 486 |
|
|
2023
Q2 | $310K | Sell |
431
-64
| -13% | -$49.3K | 0.01% | 534 |
|
|
2023
Q1 | $407K | Sell |
495
-16
| -3% | -$12.1K | 0.02% | 452 |
|
|
2022
Q4 | $369K | Sell |
511
-1,056
| -67% | -$779K | 0.02% | 422 |
|
|
2022
Q3 | $1.08M | Buy |
1,567
+858
| +121% | +$540K | 0.06% | 225 |
|
|
2022
Q2 | $419K | Buy |
709
+41
| +6% | +$26.7K | 0.03% | 352 |
|
|
2022
Q1 | $467K | Buy |
668
+63
| +10% | +$39.9K | 0.03% | 323 |
|
|
2021
Q4 | $382K | Buy |
605
+3
| +0.5% | +$1.84K | 0.02% | 358 |
|
|
2021
Q3 | $364K | Sell |
602
-41
| -6% | -$25.5K | 0.03% | 336 |
|
|
2021
Q2 | $359K | Buy |
643
+10
| +2% | +$5.07K | 0.03% | 332 |
|
|
2021
Q1 | $299K | Buy |
633
+23
| +4% | +$11.2K | 0.02% | 303 |
|
|
2020
Q4 | $295K | Buy |
610
+16
| +3% | +$8.64K | 0.03% | 256 |
|
|
2020
Q3 | $333K | Sell |
594
-302
| -34% | -$183K | 0.04% | 193 |
|
|
2020
Q2 | $559K | Buy |
896
+96
| +12% | +$54.5K | 0.07% | 107 |
|
|
2020
Q1 | $391K | Hold |
800
| – | – | 0.06% | 88 |
|
|
2019
Q4 | $300K | Hold |
800
| – | – | 0.04% | 114 |
|
|
2019
Q3 | $222K | Hold |
800
| – | – | 0.04% | 120 |
|
|
2019
Q2 | $250K | Sell |
800
-33
| -4% | -$11K | 0.04% | 109 |
|
|
2019
Q1 | $342K | Buy |
833
+33
| +4% | +$13.6K | 0.06% | 95 |
|
|
2018
Q4 | $299K | Hold |
800
| – | – | 0.07% | 96 |
|
|
2018
Q3 | $323K | Hold |
800
| – | – | 0.08% | 88 |
|
|
2018
Q2 | $276K | Hold |
800
| – | – | 0.08% | 93 |
|
|
2018
Q1 | $275K | Buy |
+800
| New | +$278K | 0.08% | 87 |
|
Other funds holding REGN
Ritholtz Wealth Management's REGN Position: Q2 2026 in Review
Ritholtz Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2026, buying an estimated $246K and bringing the position to 1,770 shares worth $1.1M. The position accounts for 0.02% of the portfolio, ranked #593.
Ritholtz Wealth Management first reported a position in REGN in Q1 2018 and has held it in 33 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Ritholtz Wealth Management held 1,770 shares of Regeneron Pharmaceuticals worth $1.1M as of Q2 2026.
- Ritholtz Wealth Management bought 362 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $246K.
- Regeneron Pharmaceuticals made up 0.02% of Ritholtz Wealth Management's portfolio in Q2 2026, its #593 holding.
- Ritholtz Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.